Symphogen A/S
Develops a method to produce antigen-specific human polyclonal antibody preparations
Lyngby, Denmark
Contact: Jeff Himawan
Case Study
Essex Woodlands identified Symphogen as a highly innovative company and first invested in Symphogen, an early stage biotech company in August 2000. Symphogen develops and successfully implements…
Learn More